Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
Top Page
Arecor Therapeutics PLC
(LSE:AREC)
Select Model
Select Model
Rating:46Neutral
Price Target:
65.00 p
▼(-23.53% Downside)
Action:ReiteratedDate:04/14/26
The score is held down primarily by weak financial performance (sharp 2025 revenue decline, continued operating losses, and ongoing cash burn) and bearish technical signals (below major moving averages with negative MACD). A low-debt balance sheet provides some stability, but valuation is not a clear positive due to negative earnings and no dividend support.
Positive Factors
Low leverage / strong balance sheet
The company’s very low leverage and minimal reported debt provide durable financial flexibility. With debt-to-equity around 0.02–0.04 in prior years and only £98k debt in 2025, Arecor has structural capacity to fund R&D, execute partnerships, or raise capital with less near-term solvency risk.
Negative Factors
Persistent negative operating cash flow
Consistent annual negative operating cash flow shows the business is not self-sustaining from operations. Over months to years this persistent cash burn forces reliance on external financing or partnerships, increasing dilution risk and constraining investment pacing for R&D or commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / strong balance sheet
The company’s very low leverage and minimal reported debt provide durable financial flexibility. With debt-to-equity around 0.02–0.04 in prior years and only £98k debt in 2025, Arecor has structural capacity to fund R&D, execute partnerships, or raise capital with less near-term solvency risk.
Read all positive factors
Arecor Therapeutics PLC (AREC) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£24.35M
Dividend YieldN/A
Average Volume (3M)40.10K
Price to Earnings (P/E)―
Beta (1Y)0.74
Revenue Growth3.31%
EPS Growth21.91%
CountryUK
Employees50
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,756,600
10 Day Avg. Volume67,644
30 Day Avg. Volume40,099
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)5.75
Price to Sales (P/S)8.20
P/FCF Ratio-13.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)£1.22M
Arecor Therapeutics PLC Business Overview & Revenue Model
Company Description
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in...
How the Company Makes Money
null...
Arecor Therapeutics PLC Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
70
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.06M | 1.71M | 5.05M | 4.57M | 2.40M | 1.16M |
| Gross Profit | -344.00K | 1.05M | 1.54M | 4.57M | 2.40M | 1.16M |
| EBITDA | -8.02M | -4.39M | -10.15M | -8.39M | -10.06M | -6.27M |
| Net Income | -8.10M | 664.00K | -10.24M | -8.55M | -9.26M | -6.17M |
Balance Sheet | ||||||
| Total Assets | 5.25M | 8.10M | 8.72M | 15.38M | 21.77M | 20.92M |
| Cash, Cash Equivalents and Short-Term Investments | 1.89M | 6.13M | 3.26M | 6.75M | 12.81M | 18.32M |
| Total Debt | 173.00K | 98.00K | 232.00K | 338.00K | 288.00K | 231.00K |
| Total Liabilities | 2.39M | 1.65M | 3.37M | 5.85M | 4.31M | 2.37M |
| Stockholders Equity | 2.86M | 6.45M | 5.35M | 9.53M | 17.45M | 18.55M |
Cash Flow | ||||||
| Free Cash Flow | -6.20M | -2.39M | -9.18M | -5.99M | -11.13M | -5.52M |
| Operating Cash Flow | -6.09M | -2.29M | -9.15M | -5.84M | -10.78M | -5.45M |
| Investing Cash Flow | 1.00K | 2.38M | 1.72M | 6.52M | -7.99M | -68.00K |
| Financing Cash Flow | 5.64M | -148.00K | 5.65M | -180.00K | 5.16M | 20.93M |
Arecor Therapeutics PLC Technical Analysis
Negative
85.00
Price Trends
71.76
Negative
75.73
Negative
70.76
Negative
Market Momentum
-2.13
Positive
32.70
Neutral
25.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AREC, the sentiment is Negative. The current price of 85 is above the 20-day moving average (MA) of 67.67, above the 50-day MA of 71.76, and above the 200-day MA of 70.76, indicating a bearish trend. The MACD of -2.13 indicates Positive momentum. The RSI at 32.70 is Neutral, neither overbought nor oversold. The STOCH value of 25.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:AREC.
Arecor Therapeutics PLC Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | £96.66M | 6.86 | 65.83% | 8.33% | -3.61% | -6.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | £24.35M | -1.64 | -197.54% | ― | 3.31% | 21.91% | |
44 Neutral | £18.13M | -9.67 | -210.32% | ― | -11.43% | 23.40% | |
43 Neutral | £684.30M | -22.92 | -48.56% | ― | 55.44% | 75.77% | |
42 Neutral | £306.18M | -1.74 | -361.23% | ― | ― | ― | |
40 Underperform | £17.56M | -6.19 | -213.66% | ― | 39.88% | 81.33% |
* Healthcare Sector Average
GB:AREC
Arecor Therapeutics PLC
66.00
28.00
73.68%
GB:AVCT
Avacta Group plc
68.00
27.00
65.85%
GB:BVXP
Bioventix
1,900.00
-372.77
-16.40%
GB:OXB
Oxford BioMedica
572.00
282.00
97.24%
GB:FAB
Fusion Antibodies Plc
14.00
7.35
110.53%
GB:APTA
Aptamer Group Plc
0.63
0.37
140.38%
Arecor Therapeutics PLC Corporate Events
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Arecor boosts cash and partnerships as AT278 insulin heads toward Phase 2
Positive
Apr 13, 2026
Arecor Therapeutics reported audited full-year 2025 results highlighting strong operational progress in its diabetes and oral peptide delivery franchises, despite lower revenue stemming from the closure of Tetris Pharma. Lead insulin candidate AT2...
Business Operations and StrategyFinancial Disclosures
Arecor sets April date for FY25 results as it advances ultra-rapid insulin and oral peptide platform
Positive
Mar 30, 2026
Arecor Therapeutics plc, a Cambridge-based clinical-stage biotech listed on AIM, develops enhanced therapeutics for diabetes, obesity and other cardiometabolic conditions, led by AT278, an ultra-concentrated ultra-rapid insulin co-developed with S...
Business Operations and StrategyPrivate Placements and Financing
Arecor Secures First Ligand Milestone to Advance Lead Insulin Program
Positive
Mar 26, 2026
Arecor Therapeutics has received its first $0.5 million commercial milestone payment from Ligand Pharmaceuticals under a royalty financing agreement tied to royalties and milestones from AT220 and AT292. The payment follows a prior $7 million upfr...
Business Operations and StrategyProduct-Related Announcements
Arecor to Spotlight Ultra-Concentrated Insulin AT278 at Key Diabetes and MedTech Conferences
Positive
Mar 9, 2026
Arecor Therapeutics will showcase its lead diabetes programme at two major industry conferences in March, underscoring its bid to position AT278 as a disruptive insulin therapy. The company will present AT278, described as the only ultra-concentra...
Business Operations and StrategyFinancial Disclosures
Arecor sharpens diabetes focus as AT278 and oral peptide platform advance
Positive
Feb 9, 2026
Arecor Therapeutics has sharpened its strategy around two core franchises, diabetes and oral peptide delivery, both in high-growth multi-billion-dollar segments, while advancing its lead insulin asset AT278 and an oral GLP-1 programme. The company...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.